TrialInternational journal of chronic obstructive pulmonary disease2012

Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD.

Dennis E Doherty et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.